Stryker (NYSE:SYK) Raised to Buy at Wall Street Zen

Key Points

• Wall Street Zen upgraded Stryker from “hold” to “buy.” The broader analyst consensus is “Moderate Buy,” with a consensus price target of $386.28.
• Stryker reported quarterly EPS of $3.69, beating expectations of $3.49, while revenue reached $6.59 billion and rose 9.4% year over year.
• At $338.85, Stryker had a $129.97 billion market capitalization; insiders sold roughly $100.7 million of shares over the past 90 days, while institutional investors owned 77.09% of the stock.

Stryker (NYSE:SYK - Get Free Report) was upgraded by investment analysts at Wall Street Zen from a "hold" rating to a "buy" rating in a note issued to investors on Saturday.

A number of other equities research analysts also recently commented on SYK. Argus set a $370.00 price objective on Stryker in a research report on Thursday, July 9th. Canaccord Genuity Group lowered their price target on Stryker from $435.00 to $400.00 and set a "buy" rating for the company in a report on Friday, May 1st. Robert W. Baird set a $385.00 price objective on shares of Stryker in a report on Friday, May 1st. Raymond James Financial set a $370.00 target price on shares of Stryker in a report on Friday, July 31st. Finally, Citizens Jmp decreased their price target on shares of Stryker from $440.00 to $400.00 and set a "market outperform" rating on the stock in a report on Monday, August 3rd. One equities research analyst has rated the stock with a Strong Buy rating, seventeen have assigned a Buy rating and five have given a Hold rating to the stock. Based on data from MarketBeat.com, Stryker currently has a consensus rating of "Moderate Buy" and a consensus target price of $386.28.

Stryker Price Performance

Stryker stock opened at $338.85 on Friday. The stock has a market capitalization of $129.97 billion, a P/E ratio of 35.11, a P/E/G ratio of 2.15 and a beta of 0.76. Stryker has a 12-month low of $281.00 and a 12-month high of $396.86. The company has a debt-to-equity ratio of 0.59, a current ratio of 2.16 and a quick ratio of 1.33. The firm's 50-day moving average is $320.11 and its two-hundred day moving average is $334.13.

Stryker (NYSE:SYK - Get Free Report) last announced its quarterly earnings data on Thursday, July 30th. The medical technology company reported $3.69 earnings per share (EPS) for the quarter, beating the consensus estimate of $3.49 by $0.20. Stryker had a net margin of 14.43% and a return on equity of 23.63%. The business had revenue of $6.59 billion for the quarter, compared to the consensus estimate of $6.58 billion. During the same quarter in the prior year, the firm posted $3.13 earnings per share. The company's quarterly revenue was up 9.4% compared to the same quarter last year. Stryker has set its FY 2026 guidance at 14.950-15.100 EPS. Equities analysts predict that Stryker will post 15.02 earnings per share for the current year.

Insider Buying and Selling at Stryker

In other Stryker news, VP M Kathryn Fink sold 5,220 shares of the business's stock in a transaction that occurred on Monday, May 11th. The shares were sold at an average price of $283.85, for a total transaction of $1,481,697.00. Following the completion of the sale, the vice president directly owned 13,137 shares in the company, valued at $3,728,937.45. The trade was a 28.44% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, Director Ronda E. Stryker sold 310,000 shares of the stock in a transaction on Tuesday, May 26th. The stock was sold at an average price of $312.23, for a total transaction of $96,791,300.00. Following the completion of the sale, the director directly owned 1,924,880 shares of the company's stock, valued at $601,005,282.40. The trade was a 13.87% decrease in their position. The disclosure for this sale is available in the SEC filing. Insiders have sold a total of 323,264 shares of company stock valued at $100,659,489 over the last ninety days. Corporate insiders own 4.60% of the company's stock.

Institutional Trading of Stryker

A number of hedge funds have recently made changes to their positions in the company. Brighton Jones LLC boosted its stake in Stryker by 15.4% during the 4th quarter. Brighton Jones LLC now owns 4,564 shares of the medical technology company's stock valued at $1,643,000 after acquiring an additional 609 shares during the last quarter. Schnieders Capital Management LLC. acquired a new stake in shares of Stryker in the 2nd quarter valued at about $205,000. Marshall Wace LLP lifted its position in shares of Stryker by 107.9% during the second quarter. Marshall Wace LLP now owns 5,700 shares of the medical technology company's stock worth $2,255,000 after purchasing an additional 77,831 shares during the last quarter. Nebula Research & Development LLC bought a new position in shares of Stryker during the second quarter worth about $219,000. Finally, HUB Investment Partners LLC acquired a new position in Stryker in the second quarter worth about $253,000. Hedge funds and other institutional investors own 77.09% of the company's stock.

Stryker Company Profile

Stryker Corporation is a global medical technology company that designs, manufactures and markets a broad range of products and services for use in hospitals, surgeons' offices and other healthcare facilities. Its primary business activities span orthopedics (including joint replacement implants, trauma and extremities products), surgical equipment and operating room technologies (such as visualization, navigation and powered instruments), neurotechnology and spine solutions, and patient-handling and emergency medical equipment.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Continue following MarketBeat

Add MarketBeat as your preferred source on Google to see our latest stories in your feed.

Add As Preferred Source